Literature DB >> 2946762

The interleukin 2 secretion defect in vitro in systemic lupus erythematosus is reversible in rested cultured T cells.

Y P Huang, P A Miescher, R H Zubler.   

Abstract

Interleukin 2 (IL 2) secretion in response to mitogenic stimulation in vitro is strongly reduced in circulating T lymphocytes from patients with SLE. It is still not clear how this abnormality relates to the B cell hyperactivity in the disease. Some investigators proposed that an intrinsic T helper cell defect could lead to suppressor cell dysfunction and autoimmunity. Others have found that in fact increased suppressor cell activity can cause IL 2 hyposecretion. In the present study we report that the IL 2 secretion in response to PHA plus PMA by T cells from patients with SLE, which initially was decreased by a factor of 10 as compared with the IL 2 secretion in blood donor T cells, was restored when the T cells were rested for 2 to 3 days in culture before stimulation. IL 2 hyposecretion in SLE T cells and the kinetics of normalization in culture were not changed by the addition of normal adherent cells during the stimulation with PHA/PMA, occurred in the absence of significant cell death or proliferation or change of the T4:T8 cell ratio during the resting culture, were not due to a maturation of immature T6-positive cells (less than 1.5% T6 cells in SLE T cells), and also occurred in T8-depleted T4 cells alone. Furthermore, a normalization of IL 2 secretion took place in the presence of either SLE serum or normal serum, and the addition of fresh autologous T cells to 3-day-cultured SLE T cells did not cause suppression of IL 2 secretion. These data show that some rapidly reversible defect occurs in circulating T helper cells in SLE. That this could reflect an exhaustion of T helper cells that have been activated in vivo is discussed.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2946762

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  23 in total

1.  Reversible interleukin-2 response defects in systemic lupus erythematosus.

Authors:  R J Warrington; P J Sauder; J Homik; W Ofosu-Appiah
Journal:  Clin Exp Immunol       Date:  1989-08       Impact factor: 4.330

2.  Increased polyamines may downregulate interleukin 2 production in rheumatoid arthritis.

Authors:  E Flescher; T L Bowlin; A Ballester; R Houk; N Talal
Journal:  J Clin Invest       Date:  1989-04       Impact factor: 14.808

Review 3.  Mechanisms of physiologic B cell responses and B cell hyperactivity in systemic lupus erythematosus.

Authors:  R H Zubler; Y P Huang; P A Miescher
Journal:  Springer Semin Immunopathol       Date:  1986

4.  Interleukin-2 production in Brown-Norway rats with HgCl2-induced autoimmune disease: paradoxical in vivo versus in vitro findings.

Authors:  D Baran; O Lantz; P Dosquet; A Sfaksi; P Druet
Journal:  Clin Exp Immunol       Date:  1988-09       Impact factor: 4.330

5.  The B-cell activation pathway in human systemic lupus erythematosus: imbalanced in vitro production of lymphokines and association with serum analytical findings.

Authors:  M L Gaspar; M Alvarez-Mon; C Gutierrez
Journal:  J Clin Immunol       Date:  1988-07       Impact factor: 8.317

6.  Spontaneous recovery of the decreased expression in vitro of interleukin 2 receptors in rheumatoid arthritis.

Authors:  C Plater-Zyberk; K A Rockett; R N Maini
Journal:  Clin Exp Immunol       Date:  1988-07       Impact factor: 4.330

7.  Modulation of the IL-2 production defect in vitro in Graves' disease.

Authors:  Z Eisenstein; E Engelsman; M Weiss; Y Kalechman; B Sredni
Journal:  Clin Exp Immunol       Date:  1994-05       Impact factor: 4.330

8.  Impaired T-cell activation in patients with systemic lupus erythematosus.

Authors:  S Sierakowski; E J Kucharz; R W Lightfoot; J S Goodwin
Journal:  J Clin Immunol       Date:  1989-11       Impact factor: 8.317

9.  Defective expression and tyrosine phosphorylation of the T cell receptor zeta chain in peripheral blood T cells from systemic lupus erythematosus patients.

Authors:  M Pang; Y Setoyama; K Tsuzaka; K Yoshimoto; K Amano; T Abe; T Takeuchi
Journal:  Clin Exp Immunol       Date:  2002-07       Impact factor: 4.330

10.  Interleukin 2 production in a family with systemic lupus erythematosus and a C4Q0 heterozygous inheritance.

Authors:  C Gutierrez; E Cabrero; J L Vicario; M Martín Villa; M A Rengel; F J Gomez Campdera; M Yebra; E Fernández-Cruz; A Arnaiz Villena
Journal:  Ann Rheum Dis       Date:  1991-08       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.